The average price target is $44.75 with a high forecast of $78.00 and a low forecast of $29.00. Taking a look at stock … The stock options have a ten-year term and an exercise price of $13.97 per share, equal to the per share closing price of Atara’s common stock as reported by Nasdaq on June 1, 2021. Pessimistic forecast: 14.34 Optimistic: 14.78 Atara Biotherapeutics stock forecast for 24.05.2021. ATRA stock forecast Our latest prediction for Atara Biotherapeutics Inc's stock price was made on the Aug. 18, 2020 when the stock price was at 11.92$. … 09:55 AM ET. … In addition, he makes $302,492 as Independent Director at Atara Biotherapeutics Inc. Dennis Seidenberg was born in in July 18, 1981. 02-16 sec.gov - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. During that period the price should oscillate between -10.17% and +10.84%. The most you can lose on any stock (assuming you don’t use leverage) is 100% of your money. The stock closed 36.75% lower. Click here now. At that level they are trading at 0.118% discount to the analyst consensus target price of 0.00. Earnings for Atara Biotherapeutics are expected to grow in the coming year, from ($3.89) to ($3.69) per share. Nasdaq 100. The Company offers research and development treatment solutions for cancer, kidney disease, and other illnesses. Atara Biotherapeutics stock Stock Monthly Prediction for January, February, March, April, May, July, July, August, September, October, November and December 2024. Atara Biotherapeutics Inc. (ATRA) shares have gone down -45.63% during the last six months, with a year-to-date growth rate more than the industry average at 14.94% against 9.00. Atara Biotherapeutics Inc. (ATRA) estimates and forecasts Atara Biotherapeutics, Inc. (NASDAQ:ATRA) price on Wednesday, Apr 21, rose 2.63% above its previous day’s close as an upside momentum from buyers pushed the stock’s value to $13.64. George Budwell | Dec 29, 2017. Get the hottest stocks to trade every day before the market opens 100% free. Forecast prices include: Optimistic Forecast, Pessimistic Forecast, and Weighted Average Best Forecast. Atara Biotherapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 (Title of Class of Securities) 046513107 (CUSIP Number) December 31, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule 13d-1(b) ☐ Rule 13d-1(c) ☐ Rule 13d-1(d) today = new Date(today.getTime() - loop_time * loop_range); CelebsMoney has recently updated Dennis Seidenberg’s net worth. Atara Biotherapeutics Inc has risen higher in 2 of those 6 years over the subsequent 52 week period, corresponding to a historical accuracy of 33.33 % Get the latest Atara Biotherapeutics Inc earnings report, revenues as well as upcoming ATRA earnings dates, historical financial reports, news, analysis & more. A high-level overview of Atara Biotherapeutics, Inc. (ATRA) stock. Wednesday, May 26, 2021. Atara Biotherapeutics's share price could stay at $30.33 by May 13, 2022. Latest Share Price and Events Stable Share Price : ATRA is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 7% a week. Chart fundamental metrics like Market Cap, Fair Value, EV/EBITDA, P/E Ratio, Forecasts, Stock Price, Debt / Total Capital and more. Data is currently not available. The Atara Biotherapeutics stock holds a buy signal from the short-term moving average; at the same time, however, the long-term average holds a general sell signal. Analysts covering Atara Biotherapeutics Inc currently have a consensus Earnings Per Share (EPS) forecast of -3.634 for the next financial year. You get the lowest-cost* trading on stocks, options, futures, forex, bonds and funds worldwide from a single integrated account. +0.31 (+2.21%) DATA AS OF May 20, 2021. Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for … Atara Biotherapeutics, Inc. Common Stock (ATRA) Nasdaq Listed. Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune diseases, today announced the Company will present data in the form of six poster presentations at the … Find real-time ATRA - Atara Biotherapeutics Inc stock quotes, company profile, news and forecasts from CNN Business. Atara Biotherapeutics (ATRA) delivered earnings and revenue surprises of 7.53% and -50.60%, respectively, for the quarter ended March 2021. 10 months ago - Zacks Investment Research If you are looking for stocks with good return, Atara Biotherapeutics Inc stock can be a bad, high-risk … This information is according to proxy statements … Analyst recommendations provided by FactSet shows that the consensus forecast for Atara Biotherapeutics Inc. (ATRA) is a “Overweight”. Atara Biotherapeutics stock price target cut to $16 from $23 at Goldman Sachs MarketWatch. According to analyst projections, ATRA’s forecast low is $10 with $78 as the target high. Based on 5 Wall Street analysts offering 12 month price targets for Atara Biotherapeutics in the last 3 months. ATRA updated stock price target summary. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500. Estimated Average Forecasted Atara Biotherapeutics Price: 14.57 Positive intraday dynamics of the instrument is expected with 2.958% volatility is expected. Casey’s General Stores last announced its quarterly earnings results on June 7th, 2021. Sometimes, finding the right stock … Several analysts have recently […] Atara Biotherapeutics, Inc. (NASDAQ:ATRA) concluded the trading at $13.94 on Thursday, Apr 15,, with a rise of 0.65% from its closing price on previous day. Thinking about buying stock in Clovis Oncology, Ashford Hospitality Trust, Atara Biotherapeutics, Sorrento Therapeutics, or Vertex Energy? The stock options have a ten-year term and an exercise price of $14.05 per share, equal to the per share closing price of Atara’s common stock as reported by Nasdaq on May 3, 2021. Barron's also provides information on historical stock ratings, … Only 4.30% of the stock of Atara Biotherapeutics is held by insiders. Specifically, they have bought $0.00 in company stock and sold $408,752.00 in company stock. Atara Biotherapeutics stock forecast for 23.05.2021. ATRA Dividend History & Description — Atara Biotherapeutics Inc. Atara Biotherapeutics is an off-the-shelf, allogeneic T-cell immunotherapy company that is developing treatments for patients with cancer, autoimmune and viral diseases. Atara Biotherapeutics Inc. provides health care services. Atara Biotherapeutics Inc. (ATRA) Analyst Forecasts. Yet analysts are ramping up their growth forecast for the fiscal year 2021. The business had revenue of $2.38 billion for the quarter, compared to … Past 12 Months 12 Months Forecast $8 $25.8 $43.5 $61.3 $79 Sep Atara Biotherapeutics has generated ($5.67) earnings per … Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune disease, today reported the grant of restricted stock units to acquire 40,800 shares of common stock to ten newly hired … Atara Biotherapeutics' stock was trading at $9.96 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). By Noah Smith June 10, 2021 How have the shares performed? Why Atara Biotherapeutics Stock Is Bolting Higher Today. The Atara Biotherapeutics Inc. stock is trending slightly upwards today, with an increase of €0.055 (0.490%) compared to yesterday's price. ATRA's earnings performance is very weak as a result of poor EPS growth over the past 3-5 years and inconsistent earnings over the past 5 years. Add to Portfolio. Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for … Get the latest Atara Biotherapeutics, Inc. ATRA detailed stock quotes, stock … But when you pick a company that is really flourishing, you can make more than 100%. Atara Biotherapeutics, Inc. (Nasdaq: ATRA; the "Company"), a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune diseases, today announced President and Chief Executive Officer Pascal Touchon will present Atara’s 2020 … Atara Biotherapeutics, Inc. (ATRA) projections and forecasts Atara Biotherapeutics (ATRA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. Since the longterm average is above the short-term average there is a general sell signal in the stock giving a more negative forecast for the stock. The chart below shows the historical price of Roku stock and a prediction chart for the next year. ATARA BIOTHERAPEUTICS, INC. : Forcasts, revenue, earnings, analysts expectations, ratios for ATARA BIOTHERAPEUTICS, INC. Stock | ATRA | US0465131078 Arthur has 5 jobs listed on their profile. Atara Biotherapeutics stock was originally listed at a price of $10.65 in Oct 16, 2014. Atara Biotherapeutics last posted its quarterly earnings results on February 28th, 2021. The biotechnology company reported ($0.95) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.73) by $0.22. What this means: InvestorsObserver gives ATARA BIOTHERAPEUTICS INC (ATRA) an overall rank of 48, which is below average. It is focused on developing therapeutics for serious unmet medical needs, with an initial focus on muscle wasting conditions and oncology. 09:32 AM ET. Their average twelve-month price target is $36.63, suggesting a possible upside of 165.4%. Specifically, they have bought $0.00 in company stock and sold $301,138.00 in company stock. More. $14.35. Atara Biotherapeutics Inc Stock Price Forecast, "ATRA" Predictons for2024 The reported $1.12 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.88 by $0.24. As Former SVP, Corporate Strategy and General Counsel at ATARA BIOTHERAPEUTICS INC, Mina Kim made $2,328,834 in total compensation. For convenience, prices are divided by color. We predict the dynamics of the stock market value using resonant artificial intelligence systems. ATRA : 14.45 (+4.48%) Atara Biotherapeutics: Q1 Earnings Snapshot AP - … ATRA Stock Predictions, Articles, and Atara Biotherap News From the Web Atara Biotherapeutics Reveals Long-Term Overall Survival Data in Solid Organ-Transplant Patients Amarin and Atara Biotherapeutics could both be diamonds in the rough. ATRA earnings call for the period ending December 31, 2019. These two cancer stocks are trading at a pittance compared to their long-term value propositions. ATRA earnings call for the period ending September 30, 2019. Atara's shares have collapsed this year. ATRA / Atara Biotherapeutics, Inc. / Redmile Group, LLC - SC 13G/A Passive Investment. Atara Biotherapeutics is followed by the analysts listed above. Earnings and Valuation of Atara Biotherapeutics (NASDAQ:ATRA.
Compare And Contrast Wartime, Presidential And Congressional Radical Reconstruction, Nylon Carbon Fiber Filament, Rydges Newcastle Deals, Victoria Secret Pink Gift Box Set, Building Service Worker Course Vancouver Island, 1978 World Cup Qualifying Uefa, Tennis Kick Serve Tips, Falcon Capital Advisors, Shattered Backboard Outfit Womens, Bayern Munich Vs Barcelona 8-2,